What are the common side effects of amlodipine (calcium channel blocker)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amlodipine Side Effects

The most common side effects of amlodipine are peripheral edema (leg/ankle swelling) and headache, which occur in a dose-dependent manner, with edema affecting up to 10.8% of patients on 10 mg daily. 1

Most Common Side Effects (Dose-Related)

The following side effects increase with higher doses of amlodipine 1:

  • Peripheral edema: 1.8% at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg (compared to 0.6% with placebo) 1
  • Headache: Common side effect, particularly noted in comparative studies 2
  • Dizziness: 1.1% at 2.5 mg, 3.4% at 5 mg and 10 mg (compared to 1.5% with placebo) 1
  • Flushing: 0.7% at 2.5 mg, 1.4% at 5 mg, and 2.6% at 10 mg 1
  • Palpitations: 0.7% at 2.5 mg, 1.4% at 5 mg, and 4.5% at 10 mg 1

Other Common Side Effects (>1% Incidence)

Additional side effects reported more frequently than placebo include 1:

  • Fatigue: 4.5% (vs. 2.8% placebo) 1
  • Nausea: 2.9% (vs. 1.9% placebo) 1
  • Abdominal pain: 1.6% (vs. 0.3% placebo) 1
  • Somnolence: 1.4% (vs. 0.6% placebo) 1

Gender-Specific Differences

Women experience significantly higher rates of certain vasodilatory side effects compared to men 1:

  • Edema: 14.6% in women vs. 5.6% in men 1
  • Flushing: 4.5% in women vs. 1.5% in men 1
  • Palpitations: 3.3% in women vs. 1.4% in men 1

Less Common Side Effects (<1% but >0.1%)

The following adverse events have been reported but occur rarely 1:

Cardiovascular

  • Arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, peripheral ischemia, syncope, tachycardia, vasculitis 1

Neurological

  • Hypoesthesia, peripheral neuropathy, paresthesia, tremor, vertigo 1

Gastrointestinal

  • Anorexia, constipation, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia 1

Musculoskeletal

  • Arthralgia, arthrosis, muscle cramps, myalgia 1

Dermatologic

  • Angioedema, erythema multiforme, pruritus, rash (erythematous and maculopapular) 1

Other Systems

  • Sexual dysfunction, insomnia, nervousness, depression, dyspnea, abnormal vision, micturition frequency 1

Important Clinical Considerations

Mechanism of Vasodilatory Side Effects

The edema, flushing, and headache associated with amlodipine result from its potent peripheral arterial vasodilatory effects, which are characteristic of dihydropyridine calcium channel blockers 2. These effects are generally mild to moderate in severity and related to the drug's mechanism of action 3.

Tolerability Profile

  • Discontinuation due to adverse effects occurs in only approximately 1.5% of patients, which is not significantly different from placebo 1
  • Amlodipine is generally well tolerated, with most side effects being mild or moderate 1, 4
  • The gradual onset of action and long half-life (35-50 hours) contribute to better tolerability compared to short-acting dihydropyridines like immediate-release nifedipine 5

Metabolic and Laboratory Effects

Amlodipine has not been associated with clinically significant changes in routine laboratory tests 1. Specifically, no adverse effects have been observed on 1, 4:

  • Serum potassium, glucose, or lipid profiles
  • Total triglycerides or cholesterol levels
  • Uric acid, blood urea nitrogen, or creatinine

Rare Postmarketing Effects

Gynecomastia has been reported infrequently in postmarketing surveillance, though a causal relationship is uncertain 1.

Critical Safety Note

Unlike immediate-release nifedipine, amlodipine does not cause reflex tachycardia or rapid blood pressure drops, making it safer for use without concurrent beta-blocker therapy 2, 5. However, systemic hypotension remains a potential concern, particularly in patients with heart failure or severe left ventricular dysfunction 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Amlodipine: a new calcium antagonist.

American journal of hospital pharmacy, 1994

Research

An update on the safety of amlodipine.

Journal of cardiovascular pharmacology, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.